Home
About TGCT
Types of TGCT
Tumor Location
Causes of TGCT
Diagnosis
>
Imaging Features
Biopsy
Treatment
Surgery
>
Recovery
Medication
Clinical Trials
>
Vimseltinib
AMB-05X
Cabiralizumab
Emactuzumab
Radiation
Get Support
Join the Community
>
Volunteer
Support Groups
TGCT Specialists
Nutrition
Pain Management
Side Effect Management
Glossary of Terms
Educational Materials & Videos
Webinars
News
Patient Stories
About Us
Meet the Team
Contact Us
Our Store
DONATE
Home
About TGCT
Types of TGCT
Tumor Location
Causes of TGCT
Diagnosis
>
Imaging Features
Biopsy
Treatment
Surgery
>
Recovery
Medication
Clinical Trials
>
Vimseltinib
AMB-05X
Cabiralizumab
Emactuzumab
Radiation
Get Support
Join the Community
>
Volunteer
Support Groups
TGCT Specialists
Nutrition
Pain Management
Side Effect Management
Glossary of Terms
Educational Materials & Videos
Webinars
News
Patient Stories
About Us
Meet the Team
Contact Us
Our Store
DONATE
Emactuzumab
Emactuzumab (SynOx Therapeutics)
is an intravenous monoclonal antibody that was previously tested in a Phase I trial. A Phase II trial has been started in select countries. This trial is currently under
review
.